Cargando…
Relapsed Rhabdomyosarcoma
Relapsed rhabdomyosarcoma (RMS) represents a significant therapeutic challenge. Nearly one-third of patients diagnosed with localized RMS and over two-thirds of patients with metastatic RMS will experience disease recurrence following primary treatment, generally within three years. Clinical feature...
Autores principales: | Heske, Christine M., Mascarenhas, Leo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922213/ https://www.ncbi.nlm.nih.gov/pubmed/33671214 http://dx.doi.org/10.3390/jcm10040804 |
Ejemplares similares
-
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force
por: Pacenta, Holly L., et al.
Publicado: (2021) -
Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta‐analysis
por: Allen‐Rhoades, Wendy, et al.
Publicado: (2023) -
The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma()
por: Heske, Christine M., et al.
Publicado: (2016) -
IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma()
por: Wan, Xiaolin, et al.
Publicado: (2015) -
Impact of race and ethnicity on presentation and outcomes of patients treated on rhabdomyosarcoma clinical trials: A report from the Children's Oncology Group
por: Munnikhuysen, Senna R., et al.
Publicado: (2023)